M3, Inc., M3 Global Research and Social Survey Research Information Co., Ltd. (SSRI) Release Comparative Results for Medical Conditions with New Product Needs
A comparison of US versus Japan through a large-scale physician survey
FORT WASHINGTON, PA (October 13, 2015) – By utilizing a large-scale physician survey called “PatientsMap” (2014 version), Social Survey Research Information Co., Ltd. (SSRI), M3, Inc. and M3 Global Research announce the comparative results on the Top 15 medical conditions in which physicians feel the need for new pharmacological products. The survey was conducted in the U.S. from the end of December 2013 to the end of February 2014 and in Japan from the end of June 2014 to early September 2014. All of the participating physicians were from M3’s own ISO 26362 certified panel.
Over 6,000 physicians were interviewed in the U.S., and over 20,000 in Japan. According to the survey, “obesity” ranked first in the U.S., with 27.4 percent of the U.S. physicians mentioning this as a medical condition in which they wish for new products, where as “dementia” came in first for Japan with 14.5 percent of mentions.
“PatientsMap” was launched in Japan as a database product in 2009, and it uncovers the number of patients treated by 20,000 Japanese physicians in over 400 diseases conditions. In addition to the number of patients, it also uncovers new product needs. After its launch in 2009, “PatientsMap” is currently used by more than 20 pharmaceutical companies.
To view the full results from the survey click here.
Established in 1982, Social Survey Research Information Co., Ltd. (SSRI) was one of the first market research companies in Japan to focus solely on healthcare. SSRI assists both domestic and international enterprises with strategic planning and marketing research, and offers a comprehensive range of research services, from traditional face-to-face methods to internet surveys. SSRI also has various healthcare related database products and develops its own software programs for tabulation and statistical analysis. SSRI has two offices in Japan (Tokyo and Osaka) and also a regional office in China.
About M3 Group
The M3 Group operates in the U.S., Asia, and Europe with over 2 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Group provides services to health care and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, Pennsylvania, Oxford, London and Seoul.